CEO Dr. Yona Geffen presents latest clinical studies at SACHS BEFI Conference.

7-9 October 2025

Our CEO Dr. Yona Geffen, shared CYTORA’s latest clinical milestones in two critical areas of unmet need: Diabetic Foot Ulcer (DFU) and Multiple System Atrophy (MSA) at the SACHS BEFI Conference on October 7–9, 2025, in Basel, Switzerland.

​

It was rewarding to connect with colleagues, potential strategic partners, and investors in Basel, all committed to improving patient care and addressing today’s most challenging diseases.

To date, CYTORA has reached significant milestones:

​

• Successfully completed a Phase 1/2a study in DFU treatment

• Advancing to a Phase 2b DFU trial, under US FDA IND

• Currently conducting a Phase 1 study for MSA

• Planning a Phase 2 MSA trial under US FDA IND